Eton Pharmaceuticals Inc (ETON) stock forecast: Can it reach its 52-week high of $21.48

Eton Pharmaceuticals Inc [ETON] stock is trading at $19.70, up 15.07%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ETON shares have gain 13.68% over the last week, with a monthly amount glided 38.83%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Eton Pharmaceuticals Inc [NASDAQ: ETON] stock has seen the most recent analyst activity on January 23, 2025, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $33 from $17. Previously, B. Riley Securities started tracking the stock with Buy rating on January 10, 2025, and set its price target to $21. On January 06, 2025, H.C. Wainwright reiterated its Buy rating and revised its price target to $17 on the stock. Craig Hallum initiated its recommendation with a Buy and recommended $8 as its price target on May 06, 2024. In a note dated January 04, 2021, H.C. Wainwright reiterated an Buy rating on this stock and revised its target price from $20 to $15.

Eton Pharmaceuticals Inc [ETON] stock has fluctuated between $3.18 and $21.48 over the past year. Currently, Wall Street analysts expect the stock to reach $13 within the next 12 months. Eton Pharmaceuticals Inc [NASDAQ: ETON] shares were valued at $19.70 at the most recent close of the market. An investor can expect a potential drop of -34.01% based on the average ETON price forecast.

Analyzing the ETON fundamentals

Eton Pharmaceuticals Inc [NASDAQ:ETON] reported sales of 48.33M for the trailing twelve months, which represents a growth of 116.95%. Gross Profit Margin for this corporation currently stands at 0.58% with Operating Profit Margin at -0.05%, Pretax Profit Margin comes in at -0.09%, and Net Profit Margin reading is -0.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is -0.23 and Total Capital is -0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.53 points at the first support level, and at 15.37 for the second support level. However, for the 1st resistance point, the stock is sitting at 20.93, and for the 2nd resistance point, it is at 22.17.

Ratios To Look Out For

For context, Eton Pharmaceuticals Inc’s Current Ratio is 1.97. Also, the Quick Ratio is 1.43, while the Cash Ratio stands at 0.69. Considering the valuation of this stock, the price to sales ratio is 10.93, the price to book ratio is 21.61.

Transactions by insiders

Recent insider trading involved Opaleye Management Inc., 10% Owner, that happened on Oct 23 ’24 when 10000.0 shares were purchased. 10% Owner, Opaleye Management Inc. completed a deal on Oct 08 ’24 to buy 33970.0 shares. Meanwhile, 10% Owner Opaleye Management Inc. bought 16852.0 shares on Oct 04 ’24.

Related Posts

MZP News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.